Abcam Introduces Alexa Fluor 680/790 Secondary Antibodies for Fluorescent Western Blotting
Abcam plc, a global leader in the supply of innovative protein research tools, has added Alexa Fluor 680/790 secondary antibodies for fluorescent western blotting to its existing Alexa Fluor conjugated antibody range.
Produced and extensively validated in Abcam laboratories, the F:P ratios of Alexa Fluor 680/790 have been optimised to ensure high quality and performance. The expanding range offers a broad portfolio of labelled secondary antibodies with guaranteed bright staining and low background to meet the different needs of researchers undertaking multi-colour analysis.
Brian Carpenter, Product Manager, Secondary Antibodies, Abcam, commented: “The popularity of fluorescent western blotting is growing and presents many advantages compared with the traditional method. With no need for film and chemiluminesence, fluorescent western blotting is more convenient and enables greater signal stability and the ability to facilitate simultaneous multi-colour analysis on one blot. High performing antibodies are crucial for fluorescent western blotting and we’re pleased that our new Alexa Fluor680/790 secondary antibodies can support this trend.”
Abcam Alexa Fluor secondaries are ideal for scientists undertaking multi-colour staining from all research backgrounds. The addition of these products complements Abcam’s innovative RabMAb primary products and market leading primary antibody range.
Abcam Alexa Fluor secondaries are supported by expert scientific support, information-rich datasheets, and are available globally with fast delivery either directly through the Abcam website or via one of Abcam’s authorised distributors.
To find out more, please visit www.abcam.com/Fluorescent-WB
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.